Association between CTC and tumor shrinkage by TKI treatment on RCC patients

Association between CTC and tumor shrinkage by TKI treatment on RCC patients - Association between CTC and tumor shrinkage by TKI treatment on RCC patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029861

Enrollment

Registered

2018-11-07

Start date

2017-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Interventions

Sunitinib treatment Pazopanib treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with metastatic clear cell renal cell carcinoma, PS; 0-1 Patients who do not have bone marrow suppression nor liver and/or renal disfunction. Patients who would have 1st line treatment.

Exclusion criteria

Exclusion criteria: Who have other malignancy Who have allergy to TKI or pregnant

Design outcomes

Primary

Measure	Time frame
number of CTC tumor shrinkage,	—

Countries

Japan

Contacts

Public ContactTomoyuki Koguchi

Fukushima Medical University Department of Urology

gucchii@fmu.ac.jp024-547-1316

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026